Reportlinker Adds Biomarkers in Breast Cancer, 2011
NEW YORK, March 29, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Biomarkers in Breast Cancer, 2011
http://www.reportlinker.com/p0287874/Biomarkers-in-Breast-Cancer-2011.html
This report provides a comprehensive and up-to-date review of breast cancer biomarkers. Recent years have seen the discovery of significant numbers of new biomarkers and clinical data are now available on previously discovered markers not yet in common use. Collectively, these are providing insights, diagnostically and therapeutically, in key areas of breast cancer. These include diagnosis, metastasis and spread, therapy direction, response to therapy, prognosis, predisposition, drug discovery and clinical research. This report presents the studies and a utility-based classification of more than 200 breast cancer markers, reported in studies between 2003 and 2010 inclusive.
Over the last decade, research has generated a wealth of biological data that characterise the changes that occur in breast cancer. These findings have advanced the understanding of this disease, and allowed the development of more discriminating diagnostic methods and treatments. Cancer embraces multiple changes at the genetic, phenotypic, cellular and histological level and nowhere are these changes more evident than in the field of cancer biomarkers, which now embraces many thousands of studies: cells, animals and human. This report presents an up-to-date review of breast cancer biomarkers, with particular focus on the research of candidate molecules in controlled clinical studies.
Biomarkers identified in this report include: proteins, peptides, metabolites, genes and mutations, epigenetic species and other molecules. In particular, the report identifies molecules that offer minimally invasive techniques. As part of this report, biomarkers are classified by their potential utility. These areas include: diagnosis and staging (e.g. early detection); metastasis (e.g. to lymph nodes, bone); therapy directing (e.g. single and multiple drugs); response to therapy (e.g. favourable, resistance); prognosis (e.g. of relapse ); potential drug targets and diagnostic opportunities (e.g. novel proteins up-regulated in breast cancer tissues or elevated in the circulation); biomarker source (e.g. blood, tissue , urine); type (e.g. protein, gene); and function (e.g. of gene or protein).
This report presents findings on more than 200 proposed breast cancer biomarkers in a review that includes studies over the last eight years, through to May 2010. The report is presented in pdf format and provides the reader with an easy-to-read layout. Biomarkers are discussed and presented by their potential utility in key breast cancer areas, including diagnosis, metastasis, response to therapy, prognosis and disease predisposition.
The study of biomarkers is one of the most promising and dynamic areas of cancer research today, as scientists seek to extend their understanding of the disease at the biological level. These advances are giving rise to more discriminating diagnostic tools and therapies, as well as a providing a deeper understanding of genetic and phenotypic differences at the patient level, as medicine moves ever closer to more personalised therapies. While these developments create important opportunities, this rapidly evolving field is also seeing uncertainty as interest shifts from past findings, to more promising recent advances. This report provides a comprehensive review on current opportunities in this field. In addition, through a six-monthly is provided (at no additional cost) with this report, helping readers to remain current with new advances and opportunities. informed of future opportunities.
Chapter 1 Background 18
1. Alzheimer's Disease 19
1.1 Statistics and Costs 19
1.2 Histopathology 20
1.3 Amyloid Beta (Abeta) 20
1.4 Tau Proteins and Neurofibrillary Tangles 21
1.5 Cholinergic Hypothesis 22
1.6 Diagnosis 22
1.7 Cognitive Tests 23
1.8 Stages of Alzheimer's Disease 25
1.9 Treatment of AD 25
1.10 Biomarkers 26
1.11 Genetics 27
Chapter 2 CSF Biomarkers and Diagnosis 33-47
Chapter 3 Blood Biomarkers and Diagnosis 52-62
Chapter 4 CSF Biomarkers and Early Detection 65-75
Chapter 5 Blood Biomarkers and Early Detection 74-80
Chapter 6 Genetic Biomarkers 81-90
Chapter 7 Image-Based Biomarkers 93-112
Chapter 8 Other Biomarkers 117-120
Chapter 9 Discussion 124-137
Table 2.1 CSF biomarkers associated with the diagnosis of Alzheimer's Disease, once it has developed
Table 3.1 Blood biomarkers associated with the diagnosis of Alzheimer's Disease, once it has developed
Table 4.1 CSF biomarkers associated with the diagnosis of early-stage Alzheimer's Disease
Table 5.1 Blood biomarkers associated with the diagnosis of early-stage Alzheimer's Disease
Table 6.1 Genetic biomarkers associated with Alzheimer's Disease
Table 7.1 Image-based biomarkers in Alzheimer's Disease
Table 8.1 Other biomarkers in Alzheimer's Disease
Table 9.1 Blood biomarkers associated with the diagnosis of Alzheimer's Disease, once it has developed
Table 9.2 Blood biomarkers associated with the detection of early-stage Alzheimer's Disease
Table 9.3 CSF biomarkers associated with the diagnosis of Alzheimer's Disease, once it has developed
Table 9.4. CSF biomarkers associated with the diagnosis of early-stage Alzheimer's Disease
Table 9.5 Genetic biomarkers associated with Alzheimer's Disease
Table 9.6 Image-based biomarkers In Alzheimer's Disease
To order this report:
: Biomarkers in Breast Cancer, 2011
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article